CA2730011C - Methods for diagnosing and treating a heart condition in a patient - Google Patents
Methods for diagnosing and treating a heart condition in a patient Download PDFInfo
- Publication number
- CA2730011C CA2730011C CA2730011A CA2730011A CA2730011C CA 2730011 C CA2730011 C CA 2730011C CA 2730011 A CA2730011 A CA 2730011A CA 2730011 A CA2730011 A CA 2730011A CA 2730011 C CA2730011 C CA 2730011C
- Authority
- CA
- Canada
- Prior art keywords
- cartridge
- gas
- patient
- air
- flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 669
- 208000024891 symptom Diseases 0.000 claims abstract description 35
- 210000004072 lung Anatomy 0.000 claims abstract description 18
- 208000010125 myocardial infarction Diseases 0.000 claims description 54
- 238000003745 diagnosis Methods 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 6
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 252
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 252
- 239000007789 gas Substances 0.000 description 195
- 239000003570 air Substances 0.000 description 193
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 64
- 230000001225 therapeutic effect Effects 0.000 description 63
- 238000009792 diffusion process Methods 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 239000001301 oxygen Substances 0.000 description 35
- 229910052760 oxygen Inorganic materials 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- 239000011149 active material Substances 0.000 description 32
- 229960005070 ascorbic acid Drugs 0.000 description 31
- 239000011668 ascorbic acid Substances 0.000 description 31
- 235000010323 ascorbic acid Nutrition 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000003963 antioxidant agent Substances 0.000 description 22
- 235000006708 antioxidants Nutrition 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- 230000003078 antioxidant effect Effects 0.000 description 21
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 19
- 238000002664 inhalation therapy Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 229910002089 NOx Inorganic materials 0.000 description 16
- 238000010586 diagram Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 206010000891 acute myocardial infarction Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 206010063837 Reperfusion injury Diseases 0.000 description 9
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 230000010410 reperfusion Effects 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000002537 thrombolytic effect Effects 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000024883 vasodilation Effects 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 206010002388 Angina unstable Diseases 0.000 description 5
- 208000007814 Unstable Angina Diseases 0.000 description 5
- 238000003915 air pollution Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 238000002565 electrocardiography Methods 0.000 description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000009428 plumbing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 239000002478 γ-tocopherol Substances 0.000 description 4
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 4
- 241000218344 Canella Species 0.000 description 3
- 235000008499 Canella winterana Nutrition 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241001503987 Clematis vitalba Species 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000219823 Medicago Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010033296 Overdoses Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000013433 lightheadedness Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- -1 nitro drugs Chemical compound 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000006815 ventricular dysfunction Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3037614A CA3037614A1 (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8338608P | 2008-07-24 | 2008-07-24 | |
| US61/083,386 | 2008-07-24 | ||
| PCT/US2009/051695 WO2010011928A1 (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037614A Division CA3037614A1 (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2730011A1 CA2730011A1 (en) | 2010-01-28 |
| CA2730011C true CA2730011C (en) | 2019-05-07 |
Family
ID=41570625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2730011A Expired - Fee Related CA2730011C (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
| CA3037614A Abandoned CA3037614A1 (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037614A Abandoned CA3037614A1 (en) | 2008-07-24 | 2009-07-24 | Methods for diagnosing and treating a heart condition in a patient |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11000484B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2306814B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6058888B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009273911B2 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2730011C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010011928A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257328A2 (en) * | 2008-03-27 | 2010-12-08 | Nellcor Puritan Bennett LLC | Breathing assistance systems with lung recruitment maneuvers |
| EP2363163A1 (en) * | 2008-03-27 | 2011-09-07 | Nellcor Puritan Bennett LLC | Device for controlled delivery of breathing gas to a patient using multiple ventilation parameters |
| WO2010011928A1 (en) | 2008-07-24 | 2010-01-28 | Geno Llc | Methods for diagnosing and treating a heart condition in a patient |
| SI3498328T1 (sl) * | 2009-05-27 | 2021-03-31 | Mallinckrodt Hospital Products IP Limited | Pripomoček za spajanje indeksiranega ventila in sestava posode pod tlakom s pritrdilnim obročem in za linearno sprožitev sestava sprožilnika pri odvajanju tekočin s pripomočkom za reguliranje dovajanja zdravila |
| EP2531249B1 (en) * | 2010-02-01 | 2021-03-24 | VERO Biotech LLC | Nitric oxide delivery system |
| CA2797702C (en) * | 2010-04-26 | 2020-03-10 | VERO Biotech LLC. | Delivery of ultra pure nitric oxide (no) |
| US8638200B2 (en) | 2010-05-07 | 2014-01-28 | Covidien Lp | Ventilator-initiated prompt regarding Auto-PEEP detection during volume ventilation of non-triggering patient |
| US8607789B2 (en) | 2010-06-30 | 2013-12-17 | Covidien Lp | Ventilator-initiated prompt regarding auto-PEEP detection during volume ventilation of non-triggering patient exhibiting obstructive component |
| US8607790B2 (en) | 2010-06-30 | 2013-12-17 | Covidien Lp | Ventilator-initiated prompt regarding auto-PEEP detection during pressure ventilation of patient exhibiting obstructive component |
| US8607791B2 (en) | 2010-06-30 | 2013-12-17 | Covidien Lp | Ventilator-initiated prompt regarding auto-PEEP detection during pressure ventilation |
| US8607788B2 (en) | 2010-06-30 | 2013-12-17 | Covidien Lp | Ventilator-initiated prompt regarding auto-PEEP detection during volume ventilation of triggering patient exhibiting obstructive component |
| US8757153B2 (en) | 2010-11-29 | 2014-06-24 | Covidien Lp | Ventilator-initiated prompt regarding detection of double triggering during ventilation |
| US8595639B2 (en) | 2010-11-29 | 2013-11-26 | Covidien Lp | Ventilator-initiated prompt regarding detection of fluctuations in resistance |
| US8757152B2 (en) | 2010-11-29 | 2014-06-24 | Covidien Lp | Ventilator-initiated prompt regarding detection of double triggering during a volume-control breath type |
| EP2645860A4 (en) | 2010-12-03 | 2014-07-09 | Geno Llc | NITROGEN OXIDE TREATMENTS |
| US9038633B2 (en) | 2011-03-02 | 2015-05-26 | Covidien Lp | Ventilator-initiated prompt regarding high delivered tidal volume |
| AU2012262534B2 (en) | 2011-05-27 | 2016-06-02 | VERO Biotech LLC. | Method of determining vasoreactivity using inhaled nitric oxide |
| MX2014000095A (es) * | 2011-07-07 | 2014-05-28 | Janssen Diagnostics Llc | Método de análisis de trastornos cardiovasculares y usos del mismo. |
| US20130145731A1 (en) * | 2011-12-07 | 2013-06-13 | Ecolab Usa Inc. | Apparatus and method for configuring and opening product packaging |
| CN104411317A (zh) * | 2012-03-15 | 2015-03-11 | Ino治疗有限责任公司 | 用于施用高浓度一氧化碳的方法 |
| US9027552B2 (en) | 2012-07-31 | 2015-05-12 | Covidien Lp | Ventilator-initiated prompt or setting regarding detection of asynchrony during ventilation |
| TWI590837B (zh) * | 2014-03-25 | 2017-07-11 | 林信湧 | 一種用於治療心臟病之吸入式醫藥組成物及其備製方法 |
| JP6704094B2 (ja) | 2017-02-27 | 2020-06-03 | サード ポール, インコーポレイテッドThird Pole, Inc. | 酸化窒素を生成するためのシステムおよび方法 |
| MX2019009931A (es) | 2017-02-27 | 2020-07-14 | Third Pole Inc | Sistemas y metodos para generacion ambulatoria de oxido nitrico. |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
| US11754538B1 (en) * | 2018-07-18 | 2023-09-12 | Vero Biotech Inc. | Method and apparatus for automatic calibration |
| WO2020232419A1 (en) | 2019-05-15 | 2020-11-19 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
| EP3969415A4 (en) | 2019-05-15 | 2023-08-16 | Third Pole, Inc. | ELECTRODES FOR GENERATING NITROUS OXIDE |
| WO2020232414A1 (en) | 2019-05-15 | 2020-11-19 | Third Pole, Inc. | Architectures for production of nitric oxide |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| EP4167920A4 (en) | 2020-06-18 | 2024-06-12 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| WO2022082072A1 (en) | 2020-10-16 | 2022-04-21 | Third Pole, Inc. | Nitric oxide generation process controls |
| WO2023049873A1 (en) | 2021-09-23 | 2023-03-30 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
| US12569628B2 (en) | 2022-04-14 | 2026-03-10 | Third Pole, Inc. | Delivery of medicinal gas in a liquid medium |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
| GB2279014B (en) * | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
| GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US6165435A (en) * | 1998-12-24 | 2000-12-26 | Praxair Technology, Inc. | Method and production of nitric acid |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
| WO2006023616A2 (en) * | 2004-08-18 | 2006-03-02 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| CA2550417A1 (en) * | 2005-12-22 | 2007-06-22 | Institut De Cardiologie De Montreal | Method for maintaining cerebral hemispheric oxygen saturation during surgery |
| WO2010011928A1 (en) | 2008-07-24 | 2010-01-28 | Geno Llc | Methods for diagnosing and treating a heart condition in a patient |
-
2009
- 2009-07-24 WO PCT/US2009/051695 patent/WO2010011928A1/en not_active Ceased
- 2009-07-24 EP EP09801072.1A patent/EP2306814B1/en not_active Not-in-force
- 2009-07-24 AU AU2009273911A patent/AU2009273911B2/en not_active Ceased
- 2009-07-24 JP JP2011520226A patent/JP6058888B2/ja not_active Expired - Fee Related
- 2009-07-24 EP EP13188785.3A patent/EP2687086B1/en not_active Not-in-force
- 2009-07-24 US US12/508,959 patent/US11000484B2/en not_active Expired - Fee Related
- 2009-07-24 CA CA2730011A patent/CA2730011C/en not_active Expired - Fee Related
- 2009-07-24 CA CA3037614A patent/CA3037614A1/en not_active Abandoned
-
2015
- 2015-02-27 JP JP2015038636A patent/JP2015145376A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20100030091A1 (en) | 2010-02-04 |
| WO2010011928A1 (en) | 2010-01-28 |
| EP2687086B1 (en) | 2016-09-14 |
| EP2306814A4 (en) | 2011-08-31 |
| JP6058888B2 (ja) | 2017-01-11 |
| EP2687086A1 (en) | 2014-01-22 |
| EP2306814A1 (en) | 2011-04-13 |
| CA3037614A1 (en) | 2010-01-28 |
| EP2306814B1 (en) | 2013-11-27 |
| AU2009273911A1 (en) | 2010-01-28 |
| JP2015145376A (ja) | 2015-08-13 |
| JP2011529083A (ja) | 2011-12-01 |
| US11000484B2 (en) | 2021-05-11 |
| AU2009273911B2 (en) | 2016-09-08 |
| CA2730011A1 (en) | 2010-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2306814B1 (en) | Methods for diagnosing and treating a heart condition in a patient | |
| US12059661B2 (en) | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | |
| AU2008232413B2 (en) | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | |
| US8246725B2 (en) | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | |
| JP5567617B2 (ja) | 二酸化窒素（ｎｏ２）の酸化窒素（ｎｏ）への変換 | |
| US20170165293A1 (en) | Method and apparatus for scavenging plasma free hemoglobin | |
| AU2013267074B2 (en) | Conversion of Nitrogen Dioxide (NO2) to Nitric Oxide (NO) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140704 |
|
| MKLA | Lapsed |
Effective date: 20220725 |